Bayforest Capital LTD Apellis Pharmaceuticals, Inc. Transaction History
Bayforest Capital LTD
- $210 Billion
- Q3 2025
A detailed history of Bayforest Capital LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayforest Capital LTD holds 20,853 shares of APLS stock, worth $423,941. This represents 0.22% of its overall portfolio holdings.
Number of Shares
20,853
Previous 56,639
63.18%
Holding current value
$423,941
Previous $980 Million
51.87%
% of portfolio
0.22%
Previous 0.43%
Shares
4 transactions
Others Institutions Holding APLS
# of Institutions
328Shares Held
124MCall Options Held
4.12MPut Options Held
756K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...